Jenburkt Pharmaceuticals Ltd. (JENBURPH): Jenburkt Pharmaceuticals Share Price Rises Over 10% Today

Jenburkt Pharmaceuticals Share Price rises over 10% today, reaching Rs 1,213.9 with a market cap of Rs 485.49 crore.

Jenburkt Pharmaceuticals Share Price has experienced a notable rise today, reaching Rs 1,213.9, marking a 10.35% increase from the previous close of Rs 1,100.05. This significant price movement places the company's market capitalisation at Rs 485.49 crore, categorising it within the micro-cap segment.

The price rise in Jenburkt Pharmaceuticals Share Price today is noteworthy, as it reflects a strong market interest in the company's stock. While the data confirms this price event, it does not establish a specific company-related catalyst for the surge. Investors and market watchers are keenly observing the stock's performance, given its substantial gain in a single trading session.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,213.9
Previous Close	Rs 1,100.05
Today's Change	+Rs 113.85 (+10.35%)
Day Open	Rs 1,107
Day High	Rs 1,239
Day Low	Rs 1,100.25
Current Volume (BSE)	4,604
BSE Traded Volume	4,604
Combined NSE + BSE Volume	4,604
Turnover	Rs 0.56 crore
Market Capitalisation	Rs 485.49 crore
Market Cap Category	Micro Cap

Jenburkt Pharmaceuticals Ltd. (JENBURPH) traded at Rs 1,213.9. versus the previous close of Rs 1,100.05, a rise of 10.35%. The stock opened at Rs 1,107, reached Rs 1,239, touched Rs 1,100.25. Reported volume was 4,604.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 485.49 crore
P/E Ratio	13.98x
P/B Ratio	2.46x
ROE	20.66%
ROCE	26.89%
EPS	Rs 78.71
Dividend Yield	1.88%

Jenburkt Pharmaceuticals Ltd. was valued at a P/E ratio of 13.98x, a P/B ratio of 2.46x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 20.66% and ROCE of 26.89%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 78.71, dividend yield of 1.88%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Jenburkt Pharmaceuticals boasts a market capitalisation of Rs 485.49 crore, with an enterprise value reflecting its financial standing. The company's P/E ratio of 13.98 is notably lower than the industry median of 25.82, suggesting a relatively inexpensive valuation compared to its peers. The P/B ratio stands at 2.46, aligning closely with the industry average of 2.49.

The company's ROE of 20.66% and ROCE of 26.89% are both significantly higher than the industry averages, indicating strong profitability and efficient capital utilisation. The EPS of Rs 78.71 further underscores the company's earnings capability, while a dividend yield of 1.88% provides an additional return to shareholders.

These fundamental metrics highlight Jenburkt Pharmaceuticals' robust financial health and competitive positioning within the pharmaceuticals industry. The company's valuation and profitability metrics are key factors for investors considering exposure to this stock.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	13.98x
Benchmark Median P/E	25.82x
Benchmark Average P/E	80.86x
Benchmark P/E Range	3.39x to 3,385.56x
Company P/B Ratio	2.46x
Benchmark Median P/B	1.85x
Company ROE	20.66%
Benchmark Median ROE	10.59%
Company ROCE	26.89%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 485.49 crore
Benchmark Median Market Cap	Rs 146.67 crore

Jenburkt Pharmaceuticals Ltd. (JENBURPH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P/E ratio of 13.98x, which is below the benchmark median of 25.82x, a difference of -45.86%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROE of 20.66%, which is above the benchmark median of 10.59%, a difference of +95.09%. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROCE of 26.89%, which is above the benchmark median of 12.98%, a difference of +107.16%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Jenburkt Pharmaceuticals operates within the healthcare sector, specifically in the pharmaceuticals and drugs industry. The sector comprises 137 companies, with Jenburkt Pharmaceuticals' P/E ratio of 13.98 sitting below the industry median of 25.82. This positions the company as an attractive investment relative to its peers.

The company's ROE and ROCE are both above the industry medians, reflecting strong operational efficiency and profitability. The healthcare sector's performance, as indicated by the benchmark data, shows a diverse range of valuations and financial metrics, with Jenburkt Pharmaceuticals standing out due to its solid financial performance.

Investors monitoring the healthcare sector may find Jenburkt Pharmaceuticals' current valuation and profitability metrics appealing, given the broader industry context and performance benchmarks.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,945.17	30.21	0.44	-2.89	-0.26
Hikal Ltd.	HIKAL	2,835.92	0	2.35	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,652.68	39.86	8.11	28.21	26.35
Beta Drugs Ltd.	BETA	2,608.51	63.2	10	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,589.99	0	3.07	0	5.36

Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P/E ratio of 13.98x compared with the displayed peer median of 30.21x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 20.66% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 26.89% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a market capitalisation of Rs 485.49 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

In comparison to its peers, Jenburkt Pharmaceuticals demonstrates a competitive edge with its P/E ratio of 13.98, which is lower than many of its peers such as Kwality Pharmaceuticals Ltd. (39.86) and Beta Drugs Ltd. (63.2). The company's ROE of 20.66% surpasses that of Dishman Carbogen Amcis Ltd. (-2.89%) and Hikal Ltd. (15.22%).

Jenburkt Pharmaceuticals' market capitalisation of Rs 485.49 crore is smaller compared to larger peers like Dishman Carbogen Amcis Ltd. (Rs 2,945.17 crore) and Hikal Ltd. (Rs 2,835.92 crore), highlighting its position as a micro-cap stock within the industry.

Why Investors Are Watching Jenburkt Pharmaceuticals

Investors are closely monitoring Jenburkt Pharmaceuticals due to its significant price rise today and its strong financial metrics.

• Price Action: Over 10% rise in share price today.
• Technical Position: Neutral RSI indicating balanced momentum.
• Fundamental Context: Strong ROE and ROCE with attractive P/E ratio.
• Sector Positioning: Competitive within the healthcare sector.

As the stock continues to attract attention, investors will be keen to see how it performs in the coming sessions, particularly in light of its current valuation and market dynamics.

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Ltd. is a prominent player in the healthcare sector, focusing on the pharmaceuticals and drugs industry. The company is engaged in the development, manufacturing, and marketing of pharmaceutical products. With a diverse product portfolio, Jenburkt Pharmaceuticals caters to various therapeutic segments, contributing to its strong market presence.

The company's strategic focus on innovation and quality has positioned it as a reliable name in the industry. Jenburkt Pharmaceuticals' commitment to delivering effective healthcare solutions continues to drive its growth and success in the competitive pharmaceuticals market.

Track Jenburkt Pharmaceuticals Share Price on Univest

Use Jenburkt Pharmaceuticals Ltd. (JENBURPH) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors can track Jenburkt Pharmaceuticals Share Price on Univest to stay updated with live share prices, technical indicators, fundamental ratios, and market insights. Univest provides comprehensive data and analysis to help investors make informed decisions about their investments in the stock market.

Frequently Asked Questions

What is the current price of Jenburkt Pharmaceuticals Share?

Ans. The current price of Jenburkt Pharmaceuticals Share is Rs 1,213.9, reflecting a 10.35% increase from the previous close of Rs 1,100.05. The stock moved 10.35% during the session. The intraday range extended from Rs 1,100.25 to Rs 1,239.

Why did Jenburkt Pharmaceuticals Share Price rise today?

Ans. Jenburkt Pharmaceuticals Share Price rose over 10% today, but the data does not establish a specific company-related catalyst for the surge. The stock moved 10.35% during the session. The intraday range extended from Rs 1,100.25 to Rs 1,239.

What is the market capitalisation of Jenburkt Pharmaceuticals?

Ans. Jenburkt Pharmaceuticals has a market capitalisation of Rs 485.49 crore, categorising it within the micro-cap segment. The company operates in the Healthcare sector. Its P/E ratio is 13.98x. ROE is 20.66% and ROCE is 26.89%.

How does Jenburkt Pharmaceuticals' P/E ratio compare to the industry?

Ans. Jenburkt Pharmaceuticals' P/E ratio of 13.98 is below the industry median of 25.82, indicating a relatively inexpensive valuation. The company trades at a P/E ratio of 13.98x. Its P/B ratio is 2.46x.

What is Jenburkt Pharmaceuticals' position in the healthcare sector?

Ans. Jenburkt Pharmaceuticals is a competitive player in the healthcare sector, with strong financial metrics and a focus on pharmaceuticals and drugs. The stock belongs to the Healthcare sector. Its industry classification is Pharmaceuticals & Drugs.

How does Jenburkt Pharmaceuticals' ROE compare to its peers?

Ans. Jenburkt Pharmaceuticals' ROE of 20.66% is higher than many of its peers, indicating strong profitability and efficient capital utilisation. ROE stands at 20.66%. ROCE stands at 26.89%. The relevant peer median ROE is 10.59%.

How does Jenburkt Pharmaceuticals' market cap compare to its peers?

Ans. Jenburkt Pharmaceuticals' market cap of Rs 485.49 crore is smaller compared to larger peers like Dishman Carbogen Amcis Ltd. and Hikal Ltd. The company operates in the Healthcare sector. Its P/E ratio is 13.98x.